Dr. Nancy T. Chang - 08 Sep 2025 Form 3 Insider Report for Immix Biopharma, Inc. (IMMX)

Role
Director
Signature
/s/ Dr. Nancy T. Chang
Issuer symbol
IMMX
Transactions as of
08 Sep 2025
Net transactions value
$0
Form type
3
Filing time
17 Sep 2025, 08:45:28 UTC
Previous filing
05 Jun 2025
Next filing
11 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
CHANG NANCY T Director C/O IMMIX BIOPHARMA, INC., 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES /s/ Dr. Nancy T. Chang 17 Sep 2025 0001135041

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IMMX Common Stock 421,940 08 Sep 2025 Direct
holding IMMX Common Stock 496,940 08 Sep 2025 Held by Robinhood II, LP F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IMMX Non-Transferrable Warrant to Purchase Common Stock 08 Sep 2025 Common Stock 316,455 $2.00 Direct
holding IMMX Non-Transferrable Warrant to Purchase Common Stock 08 Sep 2025 Common Stock 316,455 $2.00 Held by Robinhood II, LP F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Dr. Nancy T. Chang is the general manager of Robinhood II, LP and may be deemed to beneficially own the securities held by Robinhood II, LP. Dr. Chang disclaims beneficial ownership of the securities of common stock owned directly by Robinhood II, LP, except to the extent of her pecuniary interest therein.